Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.

IF 3.4 3区医学 Q3 IMMUNOLOGY

Clinical and experimental immunology Pub Date : 2024-10-16 DOI:10.1093/cei/uxae075

Yang Zhang, Weifeng Hong, Danxue Zheng, Zongjuan Li, Yong Hu, Yixing Chen, Ping Yang, Zhaochong Zeng, Shisuo Du

{"title":"Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.","authors":"Yang Zhang, Weifeng Hong, Danxue Zheng, Zongjuan Li, Yong Hu, Yixing Chen, Ping Yang, Zhaochong Zeng, Shisuo Du","doi":"10.1093/cei/uxae075","DOIUrl":null,"url":null,"abstract":"<p><p>Preclinical data suggest that type I interferon (IFN) responsiveness is essential for the antitumor effects of radiotherapy (RT). However, its clinical value remains unclear. This study aimed to explore this from a clinical perspective. In cohort 1, data from 152 hepatocellular carcinoma (HCC) patients who received RT were analyzed. Blood samples were taken 1 day before and 2 weeks after RT. RT was found to increase serum levels of IFN-β (a subtype of IFN-I) in HCC patients (3.42 ± 1.57 to 5.51 ± 2.11 pg/ml, P < 0.01), particularly in those with favorable responses. Higher post-RT serum IFN-β levels (≥4.77 pg/ml) were associated with better progression-free survival (HR = 0.58, P < 0.01). Cohort 2 included 46 HCC patients, including 23 who underwent preoperative RT and 23 matched control HCC who received surgical resection without RT. Formalin-fixed paraffin-embedded samples were obtained. Neoadjuvant RT significantly increased IFN-β expression in tumor tissues compared to direct surgery (8.13% ± 5.19% to 15.10% ± 5.89%, P < 0.01). Higher post-RT IFN-β (>median) indicated better disease-free survival (P = 0.049). Additionally, increased CD11c+MHCII+CD141+ antigen-presenting cell subsets and CD103+CD39+CD8+ tumor-infiltrating lymphocytes were found in the higher IFN-β group (P = 0.02, P = 0.03), which may contribute to the favorable prognosis in higher IFN-β group. Collectively, these findings suggest that IFN-β response activated by radiation may serve as a prognostic biomarker for HCC patients undergoing RT.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxae075","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Preclinical data suggest that type I interferon (IFN) responsiveness is essential for the antitumor effects of radiotherapy (RT). However, its clinical value remains unclear. This study aimed to explore this from a clinical perspective. In cohort 1, data from 152 hepatocellular carcinoma (HCC) patients who received RT were analyzed. Blood samples were taken 1 day before and 2 weeks after RT. RT was found to increase serum levels of IFN-β (a subtype of IFN-I) in HCC patients (3.42 ± 1.57 to 5.51 ± 2.11 pg/ml, P < 0.01), particularly in those with favorable responses. Higher post-RT serum IFN-β levels (≥4.77 pg/ml) were associated with better progression-free survival (HR = 0.58, P < 0.01). Cohort 2 included 46 HCC patients, including 23 who underwent preoperative RT and 23 matched control HCC who received surgical resection without RT. Formalin-fixed paraffin-embedded samples were obtained. Neoadjuvant RT significantly increased IFN-β expression in tumor tissues compared to direct surgery (8.13% ± 5.19% to 15.10% ± 5.89%, P < 0.01). Higher post-RT IFN-β (>median) indicated better disease-free survival (P = 0.049). Additionally, increased CD11c+MHCII+CD141+ antigen-presenting cell subsets and CD103+CD39+CD8+ tumor-infiltrating lymphocytes were found in the higher IFN-β group (P = 0.02, P = 0.03), which may contribute to the favorable prognosis in higher IFN-β group. Collectively, these findings suggest that IFN-β response activated by radiation may serve as a prognostic biomarker for HCC patients undergoing RT.

查看原文本刊更多论文

肝细胞癌放疗后 IFN-β 增高意味着生存率提高

临床前数据表明，I型干扰素（IFN）的反应性对放射治疗（RT）的抗肿瘤效果至关重要。然而，其临床价值仍不明确。本研究旨在从临床角度探讨这一问题。在队列 1 中，分析了 152 名接受过 RT 的肝细胞癌（HCC）患者的数据。分别在 RT 前一天和 RT 后两周采集血样。研究发现，RT 可提高 HCC 患者血清中 IFN-β（IFN-I 的一种亚型）的水平（3.42 ± 1.57 至 5.51 ± 2.11 pg/mL，p < 0.01），尤其是在那些反应良好的患者中。RT后较高的血清IFN-β水平（≥ 4.77 pg/mL）与较好的无进展生存期相关（HR = 0.58，p < 0.01）。队列 2 包括 46 例 HCC 患者，其中 23 例在术前接受了 RT 治疗，23 例与之匹配的对照组 HCC 患者在未接受 RT 治疗的情况下接受了手术切除。研究人员采集了福尔马林固定石蜡包埋样本。与直接手术相比，新辅助 RT 能显著增加肿瘤组织中 IFN-β 的表达（8.13% ± 5.19% 到 15.10% ± 5.89%，P < 0.01）。RT后IFN-β（>中位数）越高，表明无病生存率越高（p = 0.049）。此外，高IFN-β组中CD11c+MHCII+CD141+抗原递呈细胞亚群和CD103+CD39+CD8+肿瘤浸润淋巴细胞增多（p = 0.02，p = 0.03），这可能是高IFN-β组预后良好的原因。总之，这些研究结果表明，辐射激活的IFN-β反应可作为接受RT治疗的HCC患者的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental immunology 医学-免疫学

CiteScore

8.40

自引率

2.20%

发文量

101

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.